Welcome to the Stocktwits Top 25 Newsletter for Week 25 of 2024!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. 

Here are the Stocktwits Top 25 Lists for Week 25:

P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

The S&P 500 Top 25 list (+0.38%) underperformed the S&P 500 index (+0.61%).

There was 1 major change to the list this week.

Check out how the momentum meter has performed vs. the S&P 500 index.

This new list from Stocktwits sifts through the noise to discover stocks above $1B market cap with high relative strength and a low social following. In other words, we help you find the strongest trends before your friends. 😉

To join thousands of other traders and investors receiving the latest “Trends With No Friends” in your inbox Sunday through Thursday, click here.

The Nasdaq 100 Top 25 list (+0.06%) underperformed the Nasdaq 100 index (+0.21%).

There were 2 major changes to the list this week.

The Russell 2000 Top 25 list (+2.51%) outperformed the Russell 2000 index (+0.79%).

There were 4 major changes to the list this week.

The Top 25 lists' Top Dawg was Silk Road Medical, which rallied 26.09%. 📈

The small-cap biotech soared after Boston Scientific agreed to purchase it for $27.50 per share. Silk Road Medical offers Boston Scientific “an innovative platform of products to prevent stroke in patients with carotid artery disease.”

It’s the latest of many acquisitions in the healthcare space, as the largest players look to use their massive cash piles to buy future growth drivers. 💰

$SILK is up 119.80% YTD.

Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲

Help us deliver the best content possible by completing this brief survey. 📝

Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧

Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 👍

Disclaimer: Stocktwits, Inc. (“Stocktwits”) operates the stocktwits.com website and Stocktwits mobile device applications (the “Apps”). Stocktwits is not a securities broker-dealer, investment adviser, or any other type of financial professional. No content on the Stocktwits platform should be considered an offer, solicitation of an offer, or advice to buy or sell securities or any other type of investment or financial product. Read the full terms & conditions here. 🔍